Document is current
Any future updates will be listed below
-
Authors
Cole, Sophie
Sanchez-Santos, Maria T.
Kolovos, Spyros
Javaid, Muhammad Kassim
Pinedo-Villanueva, Rafael https://orcid.org/0000-0002-4723-5128
-
Funding
Funding for this research was provided by:
Kyowa Kirin Pharmaceutical Development
- License Information
-
More Information
Article History
Received: 16 September 2022
Accepted: 15 January 2023
First Online: 8 February 2023
Declarations
:
: Ethics approval for the RUDY Study was given from the South Central Research Ethics committee after review (LREC 14/SC/0126) in April 2014. An application with detailed analysis plan for this project was submitted and approved by the RUDY Data Access Committee in 2018 and later in September of 2019 to include further patient-reported outcome instruments.
: Not applicable.
: MKJ has received research grants from Amgen, Kyowa Kirin Services, and the International Osteoporosis Foundation; speaker fees from Amgen, Besin Healthcare, Sanofi, and Abbvie; and sits in advisory boards for UCB and Kyowa Kirin Services. RPV has received research funding from the UK NIHR, the International Osteoporosis Foundation, Kyowa Kirin Services, Fondation privée des HUG (Geneva, Switzerland), Amgen, and the Royal Osteoporosis Society, and lecture fees and/or consulting honoraria from Amgen, UCB, Kyowa Kirin Services, Astellas, the International Osteoporosis Foundation, and Mereo Biopharma.
